Danny Guy, Derrick Snowdy and the Strange Wars of Confused Men

Derrick Snowdy is probably as close to a celebrity as Canada’s private investigator community has. Starting in 2010, Snowdy burst into view as a prime mover in the political controversy colloquially known as “the busty hookers scandal.”

Snowdy proved to be a quick study at capturing an audience’s attention, ever ready to regale listeners with some of the inside stories from his investigations. So when Catalyst Capital founder Newton Glassman brought a stemwinder of a defamation litigation in 2017 against a host of hedge fund managers and journalists, it was not surprising to see Snowdy involved. (Foundation for Financial Journalism readers will recall our two 2018 investigations that looked into the quality of disclosures at Callidus Capital and Catalyst Capital, the two investment vehicles Glassman controlled. In July 2019 Catalyst amended the initial defamation claim to add Bruce Livesey, the article’s co-author, as a defendant.)

After all, given the numerous well-heeled defendants — and their lawyers, many sporting big litigation budgets — the prospects for an investigator with a knack for digging into corporate fraud seemed attractive.

For Jazz Pharmaceuticals, Failure Is the New Winning

To U.S. oncologists who treat individuals with small cell lung cancer, lurbinectedin’s arrival was a big deal. The Food and Drug Administration permitted its sale in the United States under its accelerated approval program. Then the drug failed to meet the primary endpoint of its clinical trial’s Phase III.

Illustration: Edel Rodriguez

The U5 Loophole

The U5 is one of the most important documents on Wall Street. And negotiations to discuss them can easily become a battleground where employers and employees fight over whether an upcoming exit will be classified as a resignation or a firing — and if problematic behavior is revealed.